Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine whether administering escalating doses of
cetuximab in patients with no early skin toxicity could delay the progression of disease in a
significant proportion of patients and to study the molecular signatures of response.